Company Overview of Rimonyx Pharmaceuticals, Ltd.
Rimonyx Pharmaceuticals, Ltd. engages in the discovery and development of drugs targeted at glycosaminoglycan and protein interactions. Its RX-111, an orally delivered small molecule drug for inflammatory bowel disease, is slated to enter Phase I clinical trials in the second quarter of 2005. Rimonyx Pharmaceuticals was founded by Paul Gregor in 2002. The company is based in Ness-Ziona, Israel.
Kiryat Weizmann Science Park
Sapir Street 7
Founded in 2002
972 8 940 4593
972 8 940 0917
Key Executives for Rimonyx Pharmaceuticals, Ltd.
Similar Private Companies By Industry
|Dekel Pharmaceuticals Ltd.||Middle East/Africa|
|HealOr Ltd.||Middle East/Africa|
|Bio Magnetics Ltd.||Middle East/Africa|
|Avraham Pharmaceuticals Ltd.||Middle East/Africa|
|Eloxx Pharmaceuticals, Ltd.||Middle East/Africa|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|NYC2012, Inc.||United States|
|Lawyers Committee for Civil Rights Under Law||United States|
|Rush University||United States|
|Greater Houston Partnership||United States|
Post a JobJobs
- Indianapolis, IN | AstraZenecaPosted: Dec 18
- Bridgewater, NJ | InformaticaPosted: Dec 11
- Parsippany, NJ | RGPPosted: Dec 13
- Princeton, NJ | RGPPosted: Nov 27
Sponsored Financial Commentaries
To contact Rimonyx Pharmaceuticals, Ltd., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.